CY1118794T1 - Διφασικη συνθεση κυστιδιων-λιπιδιων και μεθοδος για αγωγη τραχηλικης δυσπλασιας μεσω ενδοκολπικης απελευθερωσης - Google Patents
Διφασικη συνθεση κυστιδιων-λιπιδιων και μεθοδος για αγωγη τραχηλικης δυσπλασιας μεσω ενδοκολπικης απελευθερωσηςInfo
- Publication number
- CY1118794T1 CY1118794T1 CY20171100200T CY171100200T CY1118794T1 CY 1118794 T1 CY1118794 T1 CY 1118794T1 CY 20171100200 T CY20171100200 T CY 20171100200T CY 171100200 T CY171100200 T CY 171100200T CY 1118794 T1 CY1118794 T1 CY 1118794T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- treatment
- cervical dysplasia
- vulcan
- differential
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 206010008263 Cervical dysplasia Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108010078049 Interferon alpha-2 Proteins 0.000 abstract 3
- 229960003507 interferon alfa-2b Drugs 0.000 abstract 3
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 abstract 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 2
- 229930195722 L-methionine Natural products 0.000 abstract 2
- 229960004452 methionine Drugs 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90932407P | 2007-03-30 | 2007-03-30 | |
| PCT/CA2008/000563 WO2008119160A1 (en) | 2007-03-30 | 2008-03-27 | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118794T1 true CY1118794T1 (el) | 2017-07-12 |
Family
ID=39807744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100200T CY1118794T1 (el) | 2007-03-30 | 2017-02-14 | Διφασικη συνθεση κυστιδιων-λιπιδιων και μεθοδος για αγωγη τραχηλικης δυσπλασιας μεσω ενδοκολπικης απελευθερωσης |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8945529B2 (enExample) |
| EP (1) | EP2134353B1 (enExample) |
| JP (1) | JP5587762B2 (enExample) |
| KR (1) | KR20090130081A (enExample) |
| AU (1) | AU2008234364B2 (enExample) |
| CA (1) | CA2681565C (enExample) |
| CY (1) | CY1118794T1 (enExample) |
| DK (1) | DK2134353T3 (enExample) |
| ES (1) | ES2617063T3 (enExample) |
| HR (1) | HRP20170250T1 (enExample) |
| HU (1) | HUE033256T2 (enExample) |
| LT (1) | LT2134353T (enExample) |
| MX (1) | MX2009010405A (enExample) |
| PL (1) | PL2134353T3 (enExample) |
| PT (1) | PT2134353T (enExample) |
| SI (1) | SI2134353T1 (enExample) |
| TW (1) | TWI440477B (enExample) |
| WO (1) | WO2008119160A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008900B1 (fr) * | 2013-07-25 | 2018-03-30 | Centre Nat Rech Scient | Nanoparticules lipidiques multicompartimentees |
| US8986732B2 (en) * | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US10159646B2 (en) | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
| ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
| EP3630067A4 (en) * | 2017-05-26 | 2021-08-11 | Altum Pharmaceuticals Inc. | GIVING A BIPHASIC CANNABINOID |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| EP3849595B1 (en) | 2018-09-13 | 2025-11-19 | ModernaTX, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
| US20220401584A1 (en) | 2018-09-14 | 2022-12-22 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| KR20220070246A (ko) | 2019-09-23 | 2022-05-30 | 디디에스 리서치 인크. | 침투 증진제를 갖는 지질 소포 조성물 |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| MX2023011157A (es) | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| KR20240102989A (ko) * | 2021-11-04 | 2024-07-03 | 글로 파마, 인크. | 화장품 적용을 위한 방법 및 조성물 |
| MA71619A (fr) | 2022-07-26 | 2025-05-30 | Modernatx, Inc. | Polynucléotides modifiés pour la régulation temporelle de l'expression |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| CA2168260C (en) | 1993-07-28 | 2000-04-11 | Marianna Foldvari | Biphasic multilamellar lipid vesicles |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US5993852A (en) * | 1997-08-29 | 1999-11-30 | Pharmaderm Laboratories Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| US6656499B1 (en) * | 1999-11-12 | 2003-12-02 | Pharmaderm Laboratories, Ltd. | Composition for transdermal and dermal administration of interferon-α |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
-
2008
- 2008-03-27 EP EP08733666.5A patent/EP2134353B1/en active Active
- 2008-03-27 JP JP2010500036A patent/JP5587762B2/ja not_active Expired - Fee Related
- 2008-03-27 CA CA2681565A patent/CA2681565C/en active Active
- 2008-03-27 PL PL08733666T patent/PL2134353T3/pl unknown
- 2008-03-27 LT LTEP08733666.5T patent/LT2134353T/lt unknown
- 2008-03-27 SI SI200831765A patent/SI2134353T1/sl unknown
- 2008-03-27 HU HUE08733666A patent/HUE033256T2/hu unknown
- 2008-03-27 WO PCT/CA2008/000563 patent/WO2008119160A1/en not_active Ceased
- 2008-03-27 MX MX2009010405A patent/MX2009010405A/es active IP Right Grant
- 2008-03-27 AU AU2008234364A patent/AU2008234364B2/en not_active Ceased
- 2008-03-27 KR KR1020097022186A patent/KR20090130081A/ko not_active Ceased
- 2008-03-27 HR HRP20170250TT patent/HRP20170250T1/hr unknown
- 2008-03-27 ES ES08733666.5T patent/ES2617063T3/es active Active
- 2008-03-27 DK DK08733666.5T patent/DK2134353T3/en active
- 2008-03-27 PT PT87336665T patent/PT2134353T/pt unknown
- 2008-03-27 US US12/532,752 patent/US8945529B2/en active Active
- 2008-03-28 TW TW097111592A patent/TWI440477B/zh not_active IP Right Cessation
-
2013
- 2013-03-22 US US13/849,451 patent/US20130216610A1/en not_active Abandoned
- 2013-03-22 US US13/849,455 patent/US20130224283A1/en not_active Abandoned
-
2017
- 2017-02-14 CY CY20171100200T patent/CY1118794T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2134353A4 (en) | 2013-08-07 |
| PL2134353T3 (pl) | 2017-06-30 |
| WO2008119160A1 (en) | 2008-10-09 |
| AU2008234364B2 (en) | 2013-10-17 |
| KR20090130081A (ko) | 2009-12-17 |
| SI2134353T1 (sl) | 2017-03-31 |
| DK2134353T3 (en) | 2017-02-20 |
| US20130216610A1 (en) | 2013-08-22 |
| PT2134353T (pt) | 2017-02-15 |
| TW200846030A (en) | 2008-12-01 |
| US20130224283A1 (en) | 2013-08-29 |
| HUE033256T2 (hu) | 2017-11-28 |
| LT2134353T (lt) | 2017-03-27 |
| ES2617063T3 (es) | 2017-06-15 |
| AU2008234364A1 (en) | 2008-10-09 |
| US8945529B2 (en) | 2015-02-03 |
| JP2010522698A (ja) | 2010-07-08 |
| CA2681565C (en) | 2016-10-25 |
| US20100196453A1 (en) | 2010-08-05 |
| EP2134353B1 (en) | 2016-11-16 |
| TWI440477B (zh) | 2014-06-11 |
| MX2009010405A (es) | 2010-02-03 |
| EP2134353A1 (en) | 2009-12-23 |
| JP5587762B2 (ja) | 2014-09-10 |
| HRP20170250T1 (hr) | 2017-04-07 |
| CA2681565A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010405A (es) | Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal. | |
| JP2010522698A5 (enExample) | ||
| CY1124720T1 (el) | Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων | |
| TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| AR037629A1 (es) | Formulaciones farmaceuticas que comprenden un derivado de platino | |
| MA28740B1 (fr) | Methodes de traitement d'infections endobronchiques | |
| CO5410187A1 (es) | Formulacion oral de dosis unica de espinosad | |
| RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
| TW200501999A (en) | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier | |
| JP2004525179A5 (enExample) | ||
| WO2005019163A3 (en) | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | |
| EP1537859A3 (en) | Azithromycin dosage forms with reduced side effects | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| MY145790A (en) | Composition | |
| TW200833354A (en) | Methods of vaccine administration | |
| EP1708685A4 (en) | GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES | |
| JP6977206B2 (ja) | 自然免疫を活性化する粘膜ワクチン用アジュバント | |
| EA200802350A2 (ru) | Система доставки лекарств | |
| NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| EA200702522A1 (ru) | Система доставки лекарств в полость рта и способы ее применения | |
| GB2446341A (en) | Method and system for transdermal drug delivery | |
| ES2647584T3 (es) | Método para producir vacunas que comprende la irradiación de microorganismos en una composición que comprende aminoácidos y ortofosfato de manganeso | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| SG163500A1 (en) | Composition and method for improved bioavailiability and enhanced brain delivery of 5,5-diphenyl barbituric acid | |
| ATE555806T1 (de) | Verfahren zur verstärkung der aktivität eines therapeutischen impfstoffs |